The TRIKAFTA triple therapy - Vertex Pharma leans on a cystic fibrosis longseller

By Elena Vance, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 7:13 PM ET. Details in the imprint.

TRIKAFTA, Vertex Pharma’s triple-combination cystic fibrosis therapy, is the kind of drug you can spot in a clinic hallway before you ever see the box. Nurses talk about how patients' coughing quiets down after a few months, and parents carry notebooks filled with lung function numbers.

What TRIKAFTA actually is

TRIKAFTA is a fixed-dose combination of three active ingredients: elexacaftor, tezacaftor, and ivacaftor. It is approved by the US Food and Drug Administration (FDA) as a prescription medicine for people with cystic fibrosis who have at least one F508del mutation in the CFTR gene, covering roughly 90 percent of the CF population. The standard regimen pairs two orange tablets in the morning, containing all three components, with a blue ivacaftor tablet taken in the evening.

The drug is marketed in the US as TRIKAFTA and outside the US under the brand name KAFTRIO plus ivacaftor, but the scientific core is the same triple CFTR modulator mix. Vertex emphasizes on its official product information page that TRIKAFTA is not a cure and carries risks like elevated liver enzymes, but clinical trials showed substantial improvements in lung function, sweat chloride, and exacerbation rates compared with older regimens.

US availability, pricing and access

In the US, TRIKAFTA is available only by prescription and is dispensed primarily through specialty pharmacies. The list price is high: various US payer documents and coverage policies cite annual wholesale acquisition costs in the low to mid six-figure range per patient, often around $300,000 or more per year before rebates. That sticker shock is softened somewhat by a mix of private insurance coverage, Medicaid in many states, and Vertex’s own patient support programs for eligible individuals.

Stand in any large pediatric pulmonology center, and you will hear a social worker like Dr. Karen Smith talk more about prior authorizations than biology. Her job is to translate Vertex’s copay assistance offers and insurer formularies into real access for families. Many commercial insurers list TRIKAFTA as a preferred specialty drug for cystic fibrosis, but typically require documentation of the relevant CFTR genotype and disease severity.

How the triple therapy works

On Vertex’s official TRIKAFTA page, the company explains that elexacaftor and tezacaftor act as CFTR correctors, helping misfolded CFTR protein move to the cell surface, while ivacaftor is a CFTR potentiator that improves channel opening and chloride transport. Cystic fibrosis itself is a genetic disease characterized by thick, sticky mucus in the lungs and other organs, driven by dysfunctional or absent CFTR protein. The triple combination targets that core defect rather than just treating symptoms.

Pivotal clinical trials published in journals such as The New England Journal of Medicine and summarized in US regulatory documents showed that TRIKAFTA produced mean absolute improvements in ppFEV1 (a measure of lung function) in the 10 percentage-point range compared with placebo or older modulators, along with reduced pulmonary exacerbations. Those gains translate into fewer hospitalizations, better exercise tolerance, and, in many cases, significant weight gain in undernourished patients. You can see it in the clinic: kids on TRIKAFTA sometimes start out with sunken cheeks and narrow shoulders, then return months later looking stronger, with parents carrying larger clothing sizes.

Safety profile and monitoring

TRIKAFTA’s US prescribing information lists several important safety considerations. Liver function monitoring is mandatory: doctors are told to check transaminase and bilirubin levels before starting therapy, every three months during the first year, and annually thereafter. Elevated liver enzymes have occurred, especially in patients with preexisting liver disease, so hepatology consults are common for complex cases.

Cataracts, or lens opacities, have been reported in pediatric patients treated with ivacaftor-containing regimens. That is why many CF clinics now routinely refer children for baseline and follow-up eye exams. There are also warnings about rash, serious hypersensitivity reactions, and interactions with other drugs, particularly strong CYP3A inducers like rifampin and certain anticonvulsants that can reduce TRIKAFTA exposure. Vertex’s medication guide urges patients to tell their doctor about all medicines they take, from antibiotics to herbal supplements.

Eligibility, age ranges and label expansion

When TRIKAFTA first came to market in the US in 2019, it was approved for people 12 years and older with at least one F508del mutation. Since then, Vertex has pursued multiple label expansions. As of mid-2024, TRIKAFTA is approved in the US for children as young as 2 years old with certain CFTR mutations, following FDA reviews of pediatric trial data. That means more families now have access to CFTR modulation earlier in life, when lung damage may be less advanced.

Vertex highlights in its communications that about 90 percent of people with cystic fibrosis have at least one F508del mutation. That single statistic defines the scale of TRIKAFTA’s reach. Chief Executive Officer Reshma Kewalramani has repeatedly described the CF franchise, including TRIKAFTA, as the company’s engine for funding next-wave programs in cell and gene therapies. For families, though, the focus is much more direct: does my child’s genotype qualify, and if not, what is coming next?

Global presence and regional branding

Outside the United States, the triple CFTR combination is sold as KAFTRIO in combination with KALYDECO (ivacaftor) in the European Union and other regions. The European Medicines Agency (EMA) has authorized its use for patients with specific CFTR mutations, and health technology assessment bodies like the UK’s NICE have negotiated reimbursement agreements. Those decisions have triggered heated debates about cost versus clinical benefit, especially in publicly funded health systems.

That global footprint matters for US investors because Vertex’s CF franchise revenue is diversified across North America and Europe. Still, the US remains a key market because of its large commercially insured population and historically higher pricing. If you walk into a CF center in Boston or Houston, you are seeing the core of Vertex’s revenue story: rows of patients whose drug combinations, lab tests, and clinic visits align closely with the company’s quarterly numbers.

For US retail investors and consumers

Vertex Pharma is a US-based biotechnology company listed on the Nasdaq under the ticker VRTX. The CF franchise, led by TRIKAFTA, has generated billions of dollars in annual revenue in recent years, according to the company’s Investor Day presentations and 10-K filings. TRIKAFTA is not a consumer product in the usual sense, but for US retail investors and families living with cystic fibrosis, it sits at the intersection of medicine, finance, and policy: a longseller therapy that continues to shape both health outcomes and Vertex’s financial profile. Shares of Vertex Pharma (NASDAQ: VRTX) reflect the market’s expectations about how long that TRIKAFTA curve can hold, and how quickly the company can extend its science beyond CF.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.